Analisis of effectivity of out-patient unit based in psychoneurological dispensary

Introduction: reorganization of a Moscow psychiatric service is underway. The main object of this renovation is switching from inpatient to outpatient service. Despite the fact, that many researches were made concerning this process, articles focused on an ambulatory psychiatry center are rare.

Objective: to evaluate the efficiency of outpatient departments. To find out the most effective pharmacological ways to deal with patients who often hospitalize to psychiatric hospitals and see whether it is affective to treat them in the outpatient departments.

Material and methods: a statistical and clinical analysis of medical documents of adult patients who received psychiatric help in an outpatient psychiatry clinic and statistic data of the Gannushkins clinic.

Results: the efficiency of an outpatient hospital department and assertive care department was measured. Nosological differences were shown: Patients with schizophrenia (F20.001/2/3) and personality change due to known physiological condition (F00-09) prevailed in the assertive care department. Significantly more patients with neurotic (F40-F48), neurosis-like (F21.3),schizoaffective disorder (F25) and affective (F30-F39) disorders were treated in the outpatient hospital department. Dissimilarities in psychopharmacotherapy were also found, especially significant was the fact that anti-dementia medications were used 3 times more often in the assertive care department.

Result of complex work (medical and psychosocial) were shown. Reduction in the number of hospitalization sin the inpatient hospital hospital and the average duration of treatment there were proved. Also, attention was paid to the group of especially often hospitalized patients, among which 74%suffered from paranoid schizophrenia. The main causes of repeated hospitalizations have been identified: lack of compliance (37%), treatment resistance (30%), alcohol and drug use (22%). It was revealed that patients who used long-acting injectable antipsychotics were hospitalized more often and spent more time in the inpatient department. Those who received mood stabilizers spent less time in the hospital compared with those who did not receive this type of therapy. It is shown that treatment in the outpatient hospital department and assertive care department reduces the frequency and duration of treatment in the inpatient department.

1. Melik Guseynov D.V., Kostyuk G.P., Cheremin RA Kontseptsiya razvitiya psikhiatiricheskoy sluzhby Moskvy. Ekspertnyye kommentarii NIIOZMM. 2016. URL: http://www.niioz.ru/publications/pub20161129/

2. Shenderov K.V. s soavt Kontingent i zadachi po psikhosotsialnoy terapii bolnykh shizofreniyey i rasstroystvami shizofrenicheskogo spektra. poluchayushchikh pomoshch v usloviyakh dnevnogo statsionara Sotsialnaya i klinicheskaya psikhiatriya. 2007;17(3):10-14. (In Russ.).

3. Preobrazovaniye psikhiatricheskoy sluzhby Omskoy oblasti. Sbornik statey i normativnykh dokumentov. Omsk, 2011.

4. Stepanova O.N. Organizatsiya lechebnoy i reabilitatsionnoy raboty v otdelenii aktivnogo lecheniya i nabludeniya na domu Materialy Rossiyskoy konferentsii «Sovremennyye tendentsii organizatsii psikhiatricheskoy pomoshchi: klinicheskiye i sotsialnyye aspekty». M. 2004:111-113. (In Russ.).

5. Panteleyeva G.P., Abramova L.L., Oleychik I.V., Omelchenko M.A., Subbotskaya N.V., Sorokin S.A., Novozhenova T.E., Nikiforova I.Yu. Klinicheskiye i terapevticheskiye perspektivy metoda lecheniya angedonicheskikh endogennykh depressiy agomelatinom (valdoksanom). Zhurnal nevropatologii i psikhatrii im. S.S. Korsakova. 2015;11:47-54. (In Russ.). DOI: 10.17116/jnevro2015115112?-?

6. Dolder CR1, Nelson M., Snider M. Agomelatine treatment of major depressive disorder. — Аnn Pharmacother. 2008;42(12):1822-1831. DOI: 10.1345/aph.1L296. Epub 2008 Nov 25

7. Englisch S., Jung H.S., Lewien Aw Becker A., Nowak U., Braun H., Thiem J., Eisenacher S., Meyer-Lindenberg A., Zink M. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open Prospective Proof-of-Concept Study. J. Clin. Psychopharmacol. 2016;36(6) :597-607. DOI: 10.1097/JCP.0000000000000587

8. Bruno A., Zoccali R.A., Abenavoli E., Pandolfo G., Scimeca G., Spina E., Muscatello M.R. Augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label uncontrolled pilot study. J. Clin. Psychopharmacol. 2014;34(4) :491-494. DOI: 10.1097/JCP.0000000000000157

9. Stahl's Essential Psych о pharma со logy. 4th ed. Cambridge University Press, 2013.

10. De Risio A„ Lang A.P. History and therapeutic rationale of long acting antipsychotics. Curr. Clin. Pharmacol. 2014;9(1) :39-52.

11. Miyamoto S., Fleischhacker W.W. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. Curr. Treat Options Psychiatry. 2017;4(2):117-126. Published online 2017 Apr 19. doi: 10.1007/s40 501-017-0115-z

12. Kishimoto T., Robenzadeh A., Leucht C., Leucht S., Watanabe K., Mimura M., Borenstein M., Kane J.M., Correll C.U. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr. Bull. 2014;40(1): 192-213. doi: 10.1093/schbul/sbs150

13. Kishimoto T., Nitta M., Borenstein M., Kane J.M., Correll C.U.J. Long-acting injectable versus oral anti psychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. Clin. Psychiatry. 2013;74( 10):957-965. DOI: 10.4088/JCP.13r08440